Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 436 articles:
HTML format
Text format



Single Articles


    August 2019
  1. GALLDIKS N, Kocher M, Ceccon G, Werner JM, et al
    Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression.
    Neuro Oncol. 2019 Aug 22. pii: 5553498. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. SATTERLEE AB, Dunn DE, Lo DC, Khagi S, et al
    Tumoricidal Stem Cell Therapy Enables Killing in Novel Hybrid Models of Heterogeneous Glioblastoma.
    Neuro Oncol. 2019 Aug 17. pii: 5550912. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. VARLET P, Le Teuff G, Le Deley MC, Giangaspero F, et al
    WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
    Neuro Oncol. 2019 Aug 16. pii: 5550833. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. NGUYEN TK, Sahgal A, Detsky J, Atenafu EG, et al
    Predictors of Leptomeningeal Disease Following Hypofractionated Stereotactic Radiotherapy for Intact and Resected Brain Metastases.
    Neuro Oncol. 2019 Aug 15. pii: 5550117. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. WIRSCHING HG, Arora S, Zhang H, Szulzewsky F, et al
    Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma dependends on MMP9.
    Neuro Oncol. 2019 Aug 15. pii: 5550114. doi: 10.1093.
    PubMed     Text format    


  6. SONG Y, Jiang Y, Tao D, Wang Z, et al
    NFAT2-HDAC1 signaling contributes to the malignant phenotype of glioblastoma.
    Neuro Oncol. 2019 Aug 11. pii: 5545998. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. SHEN H, Yu M, Tsoli M, Chang C, et al
    Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas.
    Neuro Oncol. 2019 Aug 9. pii: 5545641. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. FURTNER J, Genbrugge E, Gorlia T, Bendszus M, et al
    Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
    Neuro Oncol. 2019 Aug 1. pii: 5542781. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2019
  9. GUO G, Gong K, Puliyapaddamba VT, Panchani N, et al
    Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
    Neuro Oncol. 2019 Jul 31. pii: 5541686. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. WANG T, Qiu Y, Liang L, Zheng E, et al
    H3 K27M-mutant glioma: Clinical Characteristics and Outcomes.
    Neuro Oncol. 2019 Jul 29. pii: 5540063. doi: 10.1093.
    PubMed     Text format    


  11. YOUSSEF GC, Gomez-Manzano C, Sawaya R, Fueyo J, et al
    Antitumor immune response during glioma virotherapy.
    Neuro Oncol. 2019 Jul 26. pii: 5539565. doi: 10.1093.
    PubMed     Text format    


  12. BURGENSKE DM, Yang J, Decker PA, Kollmeyer TM, et al
    Molecular Profiling of Long-Term IDH-wildtype Glioblastoma Survivors.
    Neuro Oncol. 2019 Jul 26. pii: 5539012. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. ARZT M, Monje M
    Comment on "Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia", Guo et al. 2019, Neuro-Oncology.
    Neuro Oncol. 2019 Jul 13. pii: 5532273. doi: 10.1093.
    PubMed     Text format    


  14. OSTROM QT, Adel Fahmideh M, Cote DJ, Muskens IS, et al
    Risk Factors For Childhood And Adult Primary Brain Tumors.
    Neuro Oncol. 2019 Jul 12. pii: 5532012. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. KAMSON DO
    Hypometabolic gliomas on FET-PET - Is there an inverted U-curve for survival?
    Neuro Oncol. 2019 Jul 5. pii: 5529276. doi: 10.1093.
    PubMed     Text format    


  16. CUI J, Zhang Q, Song Q, Wang H, et al
    Targeting Hypoxia Downstream Signaling Protein, CAIX, for CAR-T Cell Therapy against Glioblastoma.
    Neuro Oncol. 2019 Jul 4. pii: 5528786. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. HORBINSKI C, Ligon KL, Brastianos P, Huse JT, et al
    The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.
    Neuro Oncol. 2019 Jul 4. pii: 5528614. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. HOLDHOFF M
    Discovery of predictive biomarkers in malignant gliomas.
    Neuro Oncol. 2019 Jul 4. pii: 5528181. doi: 10.1093.
    PubMed     Text format    


    June 2019
  19. BECHER OJ
    HDAC inhibitors to the rescue in Sonic Hedgehog Medulloblastoma.
    Neuro Oncol. 2019 Jun 26. pii: 5523731. doi: 10.1093.
    PubMed     Text format    


  20. SANG Y, Hou Y, Cheng R, Zheng L, et al
    Targeting PDGFRalpha-activated Glioblastoma through Specific Inhibition of SHP-2-mediated Signaling.
    Neuro Oncol. 2019 Jun 21. pii: 5522282. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. CHANG K, Beers AL, Bai HX, Brown JM, et al
    Automatic assessment of glioma burden: A deep learning algorithm for fully automated volumetric and bi-dimensional measurement.
    Neuro Oncol. 2019 Jun 13. pii: 5514498. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. IPPEN FM, Grosch JK, Subramanian M, Kuter BM, et al
    Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Neuro Oncol. 2019 Jun 7. pii: 5512506. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. LEE EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, et al
    Barriers to Accrual and Enrollment in Brain Tumor Trials.
    Neuro Oncol. 2019 Jun 7. pii: 5513026. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. NASSIRI F, Mamatjan Y, Suppiah S, Badhiwala JH, et al
    DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
    Neuro Oncol. 2019 Jun 3. pii: 5510481. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2019
  25. EBERHART CG
    A fox with many faces: FOXR2 and embryonal brain tumors.
    Neuro Oncol. 2019 May 31. pii: 5509373. doi: 10.1093.
    PubMed     Text format    


  26. CHOI KS, Choi SH, Jeong B
    Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
    Neuro Oncol. 2019 May 24. pii: 5498696. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. ZHAO SG, Yu M, Spratt DE, Chang SL, et al
    Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
    Neuro Oncol. 2019 May 23. pii: 5497946. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. BLEDSOE JC, Breiger D, Breiger M, Shonka S, et al
    Differential Trajectories of Neurocognitive Functioning in Females versus Males Following Treatment for Pediatric Brain Tumors.
    Neuro Oncol. 2019 May 23. pii: 5498067. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. CORREA DD, Satagopan J, Martin A, Braun E, et al
    Genetic Variants and Cognitive Functions in Patients with Brain Tumors.
    Neuro Oncol. 2019 May 23. pii: 5498070. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. PAK E, MacKenzie EL, Zhao X, Pazyra-Murphy MF, et al
    A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Neuro Oncol. 2019 May 16. pii: 5490616. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. JALALI R, Goda JS
    Proton beam therapy in pediatric brain tumor patients: Improved radiation delivery techniques improve neurocognitive outcomes.
    Neuro Oncol. 2019 May 13. pii: 5488773. doi: 10.1093.
    PubMed     Text format    


  32. GALLDIKS N, Unterrainer M, Judov N, Stoffels G, et al
    Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET - Clinical relevance in glioma patients.
    Neuro Oncol. 2019 May 11. pii: 5488073. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. PAPAIOANNOU MD, Djuric U, Kao J, Karimi S, et al
    Proteomic analysis of meningiomas reveals clinically-distinct molecular patterns.
    Neuro Oncol. 2019 May 11. pii: 5488088. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. ARMSTRONG FD
    Commentary: Implications of health status, health-related quality of life, and socio-economic outcomes in survivors of childhood brain tumor survivors.
    Neuro Oncol. 2019 May 11. pii: 5488084. doi: 10.1093.
    PubMed     Text format    


  35. YOO JY, Swanner J, Otani Y, Nair M, et al
    oHSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
    Neuro Oncol. 2019 May 7. pii: 5486519. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. JONES J
    Glioblastoma single extracellular vesicle analysis profiles: wading into new oceans of tumor data.
    Neuro Oncol. 2019;21:562-564.
    PubMed     Text format    


  37. YAO J, Chakhoyan A, Nathanson DA, Yong WH, et al
    Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
    Neuro Oncol. 2019 May 4. pii: 5485508. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. VOGELBAUM MA, Yu HM
    Nodular Leptomeningeal Disease After Surgery for a Brain Metastasis - Should We Be Concerned?
    Neuro Oncol. 2019 May 3. pii: 5485425. doi: 10.1093.
    PubMed     Text format    


  39. GUO X, Pan Y, Gutmann DH
    Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia.
    Neuro Oncol. 2019 May 3. pii: 5485427. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2019
  40. DARDAUD LM, Bris C, Desquiret-Dumas V, Boisselier B, et al
    High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma.
    Neuro Oncol. 2019 Apr 26. pii: 5480712. doi: 10.1093.
    PubMed     Text format    


  41. TZARIDIS T, Gepfner-Tuma I, Hirsch S, Skardelly M, et al
    Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.
    Neuro Oncol. 2019 Apr 23. pii: 5476431. doi: 10.1093.
    PubMed     Text format    


  42. WALSH KM, Claus EB
    Diet and risk of glioma: targets for prevention remain elusive.
    Neuro Oncol. 2019 Apr 23. pii: 5476430. doi: 10.1093.
    PubMed     Text format    


  43. GREENALL SA, McKenzie M, Seminova E, Dolezal O, et al
    Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.
    Neuro Oncol. 2019 Apr 19. pii: 5475297. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. GROSS JP, Powell S, Zelko F, Hartsell W, et al
    Improved neuropsychological outcomes following proton therapy relative to x-ray therapy for pediatric brain tumor patients.
    Neuro Oncol. 2019 Apr 17. pii: 5475068. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. ACHARYA S, Wu S, Ashford JM, Tinkle CL, et al
    Association between hippocampal dose and memory in survivors of childhood or adolescent low-grade glioma: a 10-year neurocognitive longitudinal study.
    Neuro Oncol. 2019 Apr 12. pii: 5447930. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. RUDA R
    New developments and new dilemmas in lower-grade gliomas.
    Neuro Oncol. 2019 Apr 11. pii: 5440576. doi: 10.1093.
    PubMed     Text format    


  47. HOSSAIN JA, Latif MA, Ystaas LAR, Ninzima S, et al
    Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma.
    Neuro Oncol. 2019 Apr 8. pii: 5431345. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. MARISETTY AL, Lu L, Veo BL, Liu B, et al
    REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
    Neuro Oncol. 2019 Apr 6. pii: 5430241. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. PLATTEN M
    How to integrate immunotherapy into standard of care in glioblastoma.
    Neuro Oncol. 2019 Apr 2. pii: 5425530. doi: 10.1093.
    PubMed     Text format    


    March 2019
  50. FINOCCHIARO G, Pellegatta S
    NG2/CSPG4 in glioblastoma: about flexibility.
    Neuro Oncol. 2019 Mar 28. pii: 5421177. doi: 10.1093.
    PubMed     Text format    


  51. TSANG DS, Edelstein K
    Late effects after childhood brain tumour treatment: It's not just about the radiation.
    Neuro Oncol. 2019 Mar 28. pii: 5421189. doi: 10.1093.
    PubMed     Text format    


  52. CHANG SM, Messersmith H, Ahluwalia M, Andrews D, et al
    Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.
    Neuro Oncol. 2019;21:424-427.
    PubMed     Text format     Abstract available


  53. KIERAN MW, Goumnerova L, Manley P, Chi SN, et al
    Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.
    Neuro Oncol. 2019;21:537-546.
    PubMed     Text format     Abstract available


  54. ICHIMURA K
    TERT promoter mutation as a diagnostic marker for diffuse gliomas.
    Neuro Oncol. 2019 Mar 10. pii: 5372924. doi: 10.1093.
    PubMed     Text format    


  55. SAIT SF, Karajannis MA
    The new kid on the block: suicide gene therapy to modulate cancer immunosurveillance for children with high-risk malignant brain tumors.
    Neuro Oncol. 2019 Mar 10. pii: 5372925. doi: 10.1093.
    PubMed     Text format    


  56. AKAMANDISA MP, Nie K, Nahta R, Hambardzumyan D, et al
    Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Neuro Oncol. 2019 Mar 10. pii: 5372846. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. PRABHU RS, Turner BE, Asher AL, Marcrom SR, et al
    A Multi-Institutional Analysis of Presentation and Outcomes for Leptomeningeal Disease Recurrence After Surgical Resection and Radiosurgery for Brain Metastases.
    Neuro Oncol. 2019 Mar 4. pii: 5368947. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  58. MIKLJA Z, Pasternak A, Stallard S, Nicolaides T, et al
    Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.
    Neuro Oncol. 2019 Feb 26. pii: 5364813. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. KOTECHA R, Kim JM, Miller JA, Juloori A, et al
    The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis.
    Neuro Oncol. 2019 Feb 23. pii: 5364051. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. SCHOLTES C, Baust K, Weinhold L, Creutzig U, et al
    Health status, Health-Related Quality of Life and Socio-economic Outcome in Childhood Brain Tumor Survivors: a German Cohort Study.
    Neuro Oncol. 2019 Feb 22. pii: 5355656. doi: 10.1093.
    PubMed     Text format     Abstract available


  61. BJERKVIG R, Thorsen F
    Glioblastoma: a prognostic value of AMT-PET?
    Neuro Oncol. 2019;21:146-147.
    PubMed     Text format    


  62. YU L, Xu J, Liu J, Zhang H, et al
    The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.
    Neuro Oncol. 2019 Feb 12. pii: 5316233. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. SCHIFF D, van den Bent M, Vogelbaum MA, Wick W, et al
    Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.
    Neuro Oncol. 2019 Feb 8. pii: 5310249. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. LUDMIR EB, Mahajan A, Paulino AC, Jones JY, et al
    Increased Risk of Pseudoprogression among Pediatric Low-Grade Glioma Patients Treated with Proton versus Photon Radiotherapy.
    Neuro Oncol. 2019 Feb 7. pii: 5308917. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. RIJNEN SJM, Meskal I, Bakker M, De Baene W, et al
    Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning.
    Neuro Oncol. 2019 Feb 7. pii: 5308915. doi: 10.1093.
    PubMed     Text format     Abstract available


  66. KAHALLEY LS, Ris MD, Mahajan A, Okcu MF, et al
    Prospective, Longitudinal Comparison of Neurocognitive Change in Pediatric Brain Tumor Patients Treated with Proton Radiotherapy versus Surgery Only.
    Neuro Oncol. 2019 Feb 7. pii: 5308916. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. KIM JM, Miller JA, Kotecha R, Chao ST, et al
    Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
    Neuro Oncol. 2019 Feb 6. pii: 5288601. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. BRANZOLI F, Pontoizeau C, Tchara L, Di Stefano AL, et al
    Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Neuro Oncol. 2019 Feb 6. pii: 5308111. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. PIGEON H, Peres EA, Truillet C, Jego B, et al
    TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.
    Neuro Oncol. 2019 Feb 5. pii: 5307172. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2019
  70. KUAN AS, Green J, Kitahara CM, Berrington de Gonzalez A, et al
    Diet and risk of glioma: combined analysis of three large prospective studies in the UK and USA.
    Neuro Oncol. 2019 Jan 23. pii: 5299220. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. MILLER JJ, Loebel F, Juratli TA, Tummala SS, et al
    Accelerated progression of IDH mutant glioma after first recurrence.
    Neuro Oncol. 2019 Jan 22. pii: 5298917. doi: 10.1093.
    PubMed     Text format     Abstract available


  72. WENGER A, Ferreyra Vega S, Kling T, Olsson Bontell T, et al
    Intra-Tumor DNA Methylation Heterogeneity in Glioblastoma; Implications for DNA Methylation-Based Classification.
    Neuro Oncol. 2019 Jan 22. pii: 5298599. doi: 10.1093.
    PubMed     Text format     Abstract available


  73. GATES EDH, Lin JS, Weinberg JS, Hamilton J, et al
    Guiding the First Biopsy in Glioma Patients using Estimated Ki67 Maps Derived from Magnetic Resonance Imaging: Conventional versus Advanced Imaging.
    Neuro Oncol. 2019 Jan 17. pii: 5290387. doi: 10.1093.
    PubMed     Text format     Abstract available


  74. HUANG RY, Bi WL, Griffith B, Kaufmann TJ, et al
    Imaging and diagnostic advances for intracranial meningiomas.
    Neuro Oncol. 2019;21.
    PubMed     Text format     Abstract available


  75. SUPPIAH S, Nassiri F, Bi WL, Dunn IF, et al
    Molecular and translational advances in meningiomas.
    Neuro Oncol. 2019;21.
    PubMed     Text format     Abstract available


  76. BRASTIANOS PK, Galanis E, Butowski N, Chan JW, et al
    Advances in multidisciplinary therapy for meningiomas.
    Neuro Oncol. 2019;21.
    PubMed     Text format     Abstract available


  77. NASSIRI F, Price B, Shehab A, Au K, et al
    Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life.
    Neuro Oncol. 2019;21.
    PubMed     Text format     Abstract available


  78. NASSIRI F, Tabatabai G, Aldape K, Zadeh G, et al
    Challenges and opportunities in meningiomas: recommendations from the International Consortium on Meningiomas.
    Neuro Oncol. 2019;21.
    PubMed     Text format    


  79. WILLARD VW, Berlin KS, Conklin HM, Merchant TE, et al
    Trajectories of psychosocial and cognitive functioning in pediatric patients with brain tumors treated with radiation therapy.
    Neuro Oncol. 2019 Jan 8. pii: 5280722. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. ECKEL-PASSOW JE, Decker PA, Kosel ML, Kollmeyer TM, et al
    Using germline variants to estimate glioma and subtype risks.
    Neuro Oncol. 2019 Jan 8. pii: 5280678. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. MUSKENS IS, Wu AH, Porcel J, Cheng I, et al
    Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.
    Neuro Oncol. 2019 Jan 6. pii: 5274483. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. GALLDIKS N, Langen KJ, Albert NL, Chamberlain M, et al
    PET Imaging in Patients with Brain Metastasis - Report of the RANO/PET Group.
    Neuro Oncol. 2019 Jan 5. pii: 5274178. doi: 10.1093.
    PubMed     Text format     Abstract available


  83. COLMAN H
    A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma.
    Neuro Oncol. 2019;21:6-7.
    PubMed     Text format    


  84. COLMAN H
    A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma.
    Neuro Oncol. 2019;21:6-7.
    PubMed     Text format    


    December 2018
  85. ZHI T, Jiang K, Xu X, Yu T, et al
    ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1.
    Neuro Oncol. 2018 Dec 24. pii: 5260093. doi: 10.1093.
    PubMed     Text format     Abstract available


  86. AL-MAYHANI T, Heywood R, Vemireddy V, Lathia JD, et al
    A Non-Hierarchical Organisation of Tumorigenic NG2 Cells in Glioblastoma promoted by EGFR.
    Neuro Oncol. 2018 Dec 22. pii: 5257356. doi: 10.1093.
    PubMed     Text format     Abstract available


  87. FRASER K, Jo A, Giedt J, Vinegoni C, et al
    Characterization of single microvesicles in plasma from glioblastoma patients.
    Neuro Oncol. 2018 Dec 17. pii: 5250654. doi: 10.1093.
    PubMed     Text format     Abstract available


  88. CLYMER J, Bandopadhayay P
    Old meet new-the path to combination treatments in pediatric low-grade gliomas.
    Neuro Oncol. 2018 Dec 11. pii: 5238696. doi: 10.1093.
    PubMed     Text format    


    November 2018
  89. NARITA Y, Arakawa Y, Yamasaki F, Nishikawa R, et al
    A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
    Neuro Oncol. 2018 Nov 30. pii: 5219198. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. BALE TA, Jordan JT, Rapalino O, Ramamurthy N, et al
    Financially Effective Test-Algorithm to Identify an Aggressive, EGFR-amplified Variant of IDH-Wildtype, Lower-Grade Diffuse Glioma.
    Neuro Oncol. 2018 Nov 28. pii: 5212363. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. LUDMIR EB, Mandel JJ, McAleer MF, de Groot JF, et al
    Disparities along the glioblastoma clinical trials landscape.
    Neuro Oncol. 2018 Nov 26. pii: 5209731. doi: 10.1093.
    PubMed     Text format    


  92. DI STEFANO AL, Savatovsky J, Feuvret L, Villa C, et al
    CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient.
    Neuro Oncol. 2018 Nov 23. pii: 5203543. doi: 10.1093.
    PubMed     Text format    


  93. HORBINSKI C
    Differences in molecular profiles of glioblastomas according to location.
    Neuro Oncol. 2018 Nov 15. pii: 5183524. doi: 10.1093.
    PubMed     Text format    


  94. SCHIFF D, de Groot JF
    Lower-grade gliomas: the wrong target for bevacizumab.
    Neuro Oncol. 2018;20:1559-1560.
    PubMed     Text format    


  95. SPERDUTO PW, Deegan BJ, Li J, Jethwa KR, et al
    Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.
    Neuro Oncol. 2018;20:1652-1660.
    PubMed     Text format     Abstract available


  96. EISEMANN T, Costa B, Harter PN, Wick W, et al
    Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
    Neuro Oncol. 2018 Nov 10. pii: 5168873. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. PRABHU AH, Kant S, Kesarwani P, Ahmed K, et al
    Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma.
    Neuro Oncol. 2018 Nov 10. pii: 5172259. doi: 10.1093.
    PubMed     Text format     Abstract available


  98. AQUILANTI E, Miller J, Santagata S, Cahill DP, et al
    Updates in prognostic markers for gliomas.
    Neuro Oncol. 2018;20.
    PubMed     Text format     Abstract available


    October 2018
  99. DIPLAS BH, Liu H, Yang R, Hansen LJ, et al
    Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
    Neuro Oncol. 2018 Oct 22. pii: 5140128. doi: 10.1093.
    PubMed     Text format     Abstract available


  100. JOHN F, Bosnyak E, Robinette NL, Amit-Yousif AJ, et al
    Multimodal Imaging-defined Subregions in Newly-diagnosed Glioblastoma: Impact on Overall Survival.
    Neuro Oncol. 2018 Oct 22. pii: 5140157. doi: 10.1093.
    PubMed     Text format     Abstract available


  101. DE LEEUW CN, Vogelbaum MA
    Supratotal Resection in Glioma: A Systematic Review.
    Neuro Oncol. 2018 Oct 15. pii: 5131643. doi: 10.1093.
    PubMed     Text format     Abstract available


  102. KORJA M, Raj R, Seppa K, Luostarinen T, et al
    Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland.
    Neuro Oncol. 2018 Oct 12. pii: 5127281. doi: 10.1093.
    PubMed     Text format     Abstract available


  103. ACHEY RL, Gittleman H, Schroer J, Khanna V, et al
    Non-malignant and malignant meningioma incidence and survival in the elderly from 2005-2015 using the Central Brain Tumor Registry of the United States.
    Neuro Oncol. 2018 Oct 6. pii: 5122860. doi: 10.1093.
    PubMed     Text format     Abstract available


  104. WICK W, Dettmer S, Berberich A, Kessler T, et al
    N2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
    Neuro Oncol. 2018 Oct 1. pii: 5113425. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. BARAJAS RF JR, Hamilton BE, Schwartz D, McConnell HL, et al
    Combined Iron Oxide Nanoparticle Ferumoxytol and Gadolinium Contrast Enhanced MRI Defines Glioblastoma Pseudo-progression.
    Neuro Oncol. 2018 Oct 1. pii: 5113424. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2018
  106. MORAES FY, Winter J, Atenafu EG, Dasgputa A, et al
    Outcomes following SRS for small- to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose.
    Neuro Oncol. 2018 Sep 28. pii: 5108534. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. ZHANG H, Liao J, Zhang X, Zhao E, et al
    Sex difference of mutation clonality in diffuse glioma evolution.
    Neuro Oncol. 2018 Sep 25. pii: 5106960. doi: 10.1093.
    PubMed     Text format     Abstract available


  108. KORSHUNOV A, Sahm F, Zheludkova O, Golanov A, et al
    DNA-methylation profiling is a method of choice for molecular verification of pediatric WNT activated medulloblastomas.
    Neuro Oncol. 2018 Sep 25. pii: 5106618. doi: 10.1093.
    PubMed     Text format     Abstract available


  109. AJITHKUMAR T, Imbulgoda N, Rees E, Harris F, et al
    Uncommon low-grade brain tumors.
    Neuro Oncol. 2018 Sep 20. pii: 5104003. doi: 10.1093.
    PubMed     Text format     Abstract available


  110. POORE B, Yuan M, Arnold A, Price A, et al
    mTORC1 inhibition in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
    Neuro Oncol. 2018 Sep 18. pii: 5100756. doi: 10.1093.
    PubMed     Text format     Abstract available


  111. MANSOURI A, Hachem LD, Mansouri S, Nassiri F, et al
    MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
    Neuro Oncol. 2018 Sep 5. pii: 5090948. doi: 10.1093.
    PubMed     Text format     Abstract available


  112. YAMASHITA AS, da Costa Rosa M, Borodovsky A, Festuccia WT, et al
    Demethylation and epigenetic modification with 5-Azacytidine reduces IDH1 mutant glioma growth in combination with Temozolomide.
    Neuro Oncol. 2018 Sep 3. pii: 5089721. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  113. HENCH J, Bihl M, Bratic Hench I, Hoffmann P, et al
    Satisfying your neuro-oncologist: a fast approach to routine molecular glioma diagnostics.
    Neuro Oncol. 2018 Aug 30. pii: 5087930. doi: 10.1093.
    PubMed     Text format    


  114. LIEBERMAN NAP, DeGolier K, Kovar HM, Davis A, et al
    Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy.
    Neuro Oncol. 2018 Aug 28. pii: 5085631. doi: 10.1093.
    PubMed     Text format     Abstract available


  115. JACOBS DI, Fukumura K, Bainbridge MN, Armstrong GN, et al
    Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series.
    Neuro Oncol. 2018 Aug 24. pii: 5079134. doi: 10.1093.
    PubMed     Text format     Abstract available


  116. SVENSSON F, Westerman B, Wurdinger T, Bailey D, et al
    GBM Drug Bank-a new resource for glioblastoma drug discovery and informatics research.
    Neuro Oncol. 2018 Aug 20. pii: 5076955. doi: 10.1093.
    PubMed     Text format    


  117. HUANG RY, Bi WL, Weller M, Kaley T, et al
    Proposed Response Assessment and Endpoints for Meningioma Clinical Trials: Report from the Response Assessment in Neuro-Oncology (RANO) Working Group.
    Neuro Oncol. 2018 Aug 18. pii: 5076187. doi: 10.1093.
    PubMed     Text format     Abstract available


  118. OSTROM QT, Coleman W, Huang W, Rubin JB, et al
    Sex-specific gene and pathway modeling of inherited glioma risk.
    Neuro Oncol. 2018 Aug 14. pii: 5073373. doi: 10.1093.
    PubMed     Text format     Abstract available


  119. KIM JY, Park JE, Jo Y, Shim WH, et al
    Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Neuro Oncol. 2018 Aug 11. pii: 5069926. doi: 10.1093.
    PubMed     Text format     Abstract available


  120. TEJADA NEYRA MA, Neuberger U, Reinhardt A, Brugnara G, et al
    Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
    Neuro Oncol. 2018 Aug 9. pii: 5068679. doi: 10.1093.
    PubMed     Text format     Abstract available


  121. KOK JL, Teepen JC, van Leeuwen FE, Tissing WJE, et al
    Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age.
    Neuro Oncol. 2018 Aug 7. pii: 5067497. doi: 10.1093.
    PubMed     Text format     Abstract available


  122. HUANG RY, Unadkat P, Linda Bi W, George E, et al
    Response Assessment of Meningioma: 1D, 2D and Volumetric Criteria for Treatment Response and Tumor Progression.
    Neuro Oncol. 2018 Aug 2. pii: 5063817. doi: 10.1093.
    PubMed     Text format     Abstract available


  123. HARTMANN C
    Inclusion bias of patients with genetically different glioblastoma subgroups in clinical trials.
    Neuro Oncol. 2018 Aug 1. pii: 5063295. doi: 10.1093.
    PubMed     Text format    


    July 2018
  124. CHO HJ, Zhao J, Jung SW, Ladewig E, et al
    Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.
    Neuro Oncol. 2018 Jul 31. pii: 5061885. doi: 10.1093.
    PubMed     Text format     Abstract available


  125. PARK AK, Kim P, Ballester LY, Esquenazi Y, et al
    Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
    Neuro Oncol. 2018 Jul 25. pii: 5059682. doi: 10.1093.
    PubMed     Text format     Abstract available


  126. KATHAGEN-BUHMANN A, Maire CL, Weller J, Schulte A, et al
    The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have antiproliferative effects.
    Neuro Oncol. 2018 Jul 24. pii: 5057755. doi: 10.1093.
    PubMed     Text format     Abstract available


  127. SUH CH, Kim HS, Jung SC, Choi CG, et al
    2-hydroxyglutarate MR Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutant Glioma: A Systemic Review and Meta-analysis using Individual Patient Data.
    Neuro Oncol. 2018 Jul 18. pii: 5055433. doi: 10.1093.
    PubMed     Text format     Abstract available


  128. SPIEGL-KREINECKER S, Lotsch D, Neumayer K, Kastler L, et al
    TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
    Neuro Oncol. 2018 Jul 11. pii: 5052146. doi: 10.1093.
    PubMed     Text format     Abstract available


  129. LASSMAN AB, van den Bent MJ, Gan HK, Reardon DA, et al
    Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
    Neuro Oncol. 2018 Jul 5. pii: 5049251. doi: 10.1093.
    PubMed     Text format     Abstract available


  130. THEELER BJ
    De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter.
    Neuro Oncol. 2018;20:1009-1010.
    PubMed     Text format    


  131. CIMINO PJ, McFerrin L, Wirsching HG, Arora S, et al
    Copy number profiling across glioblastoma populations has implications for clinical trial design.
    Neuro Oncol. 2018 Jul 2. pii: 5047422. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  132. LEE EQ, McFaline-Figueroa JR, Cloughesy TF, Wen PY, et al
    Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?
    Neuro Oncol. 2018 Jun 27. pii: 5046042. doi: 10.1093.
    PubMed     Text format    


  133. MICHAELSEN SR, Staberg M, Pedersen H, Jensen KE, et al
    VEGF-C Sustains VEGFR2 Activation under Bevacizumab Therapy and Promotes Glioblastoma Maintenance.
    Neuro Oncol. 2018 Jun 25. pii: 5043488. doi: 10.1093.
    PubMed     Text format     Abstract available


  134. SA JK, Kim SH, Lee JK, Cho HJ, et al
    Identification of Genomic and Molecular Traits that Present Therapeutic Vulnerability to HGF-targeted therapy in Glioblastoma.
    Neuro Oncol. 2018 Jun 23. pii: 5043207. doi: 10.1093.
    PubMed     Text format     Abstract available


  135. ANDRONESI OC
    Precision oncology in the era of radiogenomics: the case of D-2HG as an imaging biomarker for mutant IDH gliomas.
    Neuro Oncol. 2018;20:865-867.
    PubMed     Text format    


  136. LAL S, Carrera D, Phillips JJ, Weiss WA, et al
    An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
    Neuro Oncol. 2018 Jun 14. pii: 5038008. doi: 10.1093.
    PubMed     Text format     Abstract available


  137. BROWN DA, Himes BT, Kerezoudis P, Chilinda-Salter YM, et al
    Insurance Correlates with Improved Access to Care and Outcome Among Glioblastoma Patients.
    Neuro Oncol. 2018 Jun 11. pii: 5035412. doi: 10.1093.
    PubMed     Text format     Abstract available


  138. KUNZ M, Albert NL, Unterrainer M, la Fougere C, et al
    Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.
    Neuro Oncol. 2018 Jun 9. pii: 5035376. doi: 10.1093.
    PubMed     Text format     Abstract available


  139. FALK DELGADO A, De Luca F, van Westen D, Falk Delgado A, et al
    Arterial Spin Labeling MR imaging for differentiation between high and low grade glioma - a meta-analysis.
    Neuro Oncol. 2018 Jun 2. pii: 5032325. doi: 10.1093.
    PubMed     Text format     Abstract available


  140. LOMBARDI G, Della Puppa A, Gardiman MP, Rossi S, et al
    Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma.
    Neuro Oncol. 2018 Jun 2. pii: 5032324. doi: 10.1093.
    PubMed     Text format    


    May 2018
  141. ZHANG L, He L, Lugano R, Roodakker K, et al
    IDH-mutation Status is Associated with Distinct Vascular Gene Expression Signatures in Lower Grade Gliomas.
    Neuro Oncol. 2018 May 29. pii: 5018656. doi: 10.1093.
    PubMed     Text format     Abstract available


  142. DASGUPTA A, Gupta T, Pungavkar S, Shirsat N, et al
    Nomograms based on Pre-operative Multi-parametric Magnetic Resonance Imaging for Prediction of Molecular Subgrouping in Medulloblastoma: Results from a Radiogenomics Study of 111 Patients.
    Neuro Oncol. 2018 May 29. pii: 5018966. doi: 10.1093.
    PubMed     Text format     Abstract available


  143. JOSEPH SK, Samaha H, Bielamowicz K, Ahmed N, et al
    Invited Response to the Comment by Caruso and Heimberger on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma" by Bielamowicz et al.
    Neuro Oncol. 2018 May 19. pii: 4999739. doi: 10.1093.
    PubMed     Text format    


  144. EICKHOFF J, Robins HI
    Survival of patients with prior anti-angiogenic therapy.
    Neuro Oncol. 2018;20:860-861.
    PubMed     Text format    


  145. BROWN NF, Williams M, Arkenau HT, Fleming RA, et al
    A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.
    Neuro Oncol. 2018 May 17. pii: 4998845. doi: 10.1093.
    PubMed     Text format     Abstract available


  146. GILLESPIE S, Monje M
    An Active Role for Neurons in Glioma Progression: Making Sense of Scherer's Structures.
    Neuro Oncol. 2018 May 17. pii: 4998849. doi: 10.1093.
    PubMed     Text format     Abstract available


  147. GEURTS M, van den Bent MJ
    Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?
    Neuro Oncol. 2018 May 15. pii: 4996074. doi: 10.1093.
    PubMed     Text format    


  148. VAN DEN BOSSCHE WBL, Kleijn A, Teunissen CE, Voerman JSA, et al
    Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    Neuro Oncol. 2018 May 15. pii: 4996453. doi: 10.1093.
    PubMed     Text format     Abstract available


  149. CLAUS EB, Cornish AJ, Broderick P, Schildkraut JM, et al
    Genome-wide association analysis identifies a meningioma risk locus at 11p15.5.
    Neuro Oncol. 2018 May 12. pii: 4995586. doi: 10.1093.
    PubMed     Text format     Abstract available


  150. CLOUGHESY TF, Landolfi J, Vogelbaum MA, Ostertag D, et al
    Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC.
    Neuro Oncol. 2018 May 12. pii: 4995454. doi: 10.1093.
    PubMed     Text format     Abstract available


  151. PUDELKO L, Edwards S, Balan M, Nyqvist D, et al
    An orthotopic glioblastoma animal model suitable for high-throughput screenings.
    Neuro Oncol. 2018 May 10. pii: 4994699. doi: 10.1093.
    PubMed     Text format     Abstract available


  152. ZACHARIAH M, Oliveira-Costa JP, Carter B, Stott SL, et al
    Blood-Based Biomarkers for the Diagnosis and Monitoring of Gliomas.
    Neuro Oncol. 2018 May 9. pii: 4994194. doi: 10.1093.
    PubMed     Text format    


  153. GUPTA N, Goumnerova LC, Manley P, Chi SN, et al
    Prospective Feasibility and Safety Assessment of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma.
    Neuro Oncol. 2018 May 5. pii: 4993208. doi: 10.1093.
    PubMed     Text format     Abstract available


  154. KARACHI A, Dastmalchi F, Mitchell D, Rahman M, et al
    Temozolomide for Immunomodulation in the Treatment of Glioblastoma.
    Neuro Oncol. 2018 May 4. pii: 4992672. doi: 10.1093.
    PubMed     Text format     Abstract available


  155. PAECH D, Windschuh J, Oberhollenzer J, Dreher C, et al
    Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multi-pool CEST MRI at 7.0 Tesla.
    Neuro Oncol. 2018 May 4. pii: 4992691. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  156. STADLBAUER A, Zimmermann M, Doerfler A, Oberndorfer S, et al
    Intratumoral Heterogeneity of Oxygen Metabolism and Neovascularization Uncovers Two Survival Relevant Subgroups of IDH1 Wild-type Glioblastoma.
    Neuro Oncol. 2018 Apr 28. pii: 4989834. doi: 10.1093.
    PubMed     Text format     Abstract available


  157. ELLINGSON BM, Abrey LE, Garcia J, Chinot O, et al
    Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo.
    Neuro Oncol. 2018 Apr 20. pii: 4979515. doi: 10.1093.
    PubMed     Text format     Abstract available


  158. HERSH DS, Harder BG, Roos A, Peng S, et al
    The TNF Receptor Family Member Fn14 is Highly Expressed in Recurrent Glioblastoma (GBM) and in GBM Patient-Derived Xenografts With Acquired Temozolomide Resistance.
    Neuro Oncol. 2018 Apr 20. pii: 4979510. doi: 10.1093.
    PubMed     Text format     Abstract available


  159. DU Z, Brewster R, Merrill PH, Chmielecki J, et al
    Meningioma transcription factors link cell lineage with systemic metabolic cues.
    Neuro Oncol. 2018 Apr 12. pii: 4969420. doi: 10.1093.
    PubMed     Text format     Abstract available


  160. KOGA T, Li B, Figueroa JM, Ren B, et al
    Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
    Neuro Oncol. 2018 Apr 12. pii: 4969527. doi: 10.1093.
    PubMed     Text format     Abstract available


  161. CARUSO H, Heimberger AB
    Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma".
    Neuro Oncol. 2018 Apr 10. pii: 4965825. doi: 10.1093.
    PubMed     Text format    


  162. HEGI ME, Kleihues P, Wen PY, Suva ML, et al
    Toward methylation-based classification of central nervous system tumors.
    Neuro Oncol. 2018;20:579-581.
    PubMed     Text format    


  163. LEVIN VA, Ellingson BM
    Understanding brain penetrance of anticancer drugs.
    Neuro Oncol. 2018;20:589-596.
    PubMed     Text format     Abstract available


  164. WILKE C, Grosshans D, Duman J, Brown P, et al
    Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults.
    Neuro Oncol. 2018;20:597-607.
    PubMed     Text format     Abstract available


  165. MENDEZ JS, Ostrom QT, Gittleman H, Kruchko C, et al
    The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.
    Neuro Oncol. 2018;20:687-694.
    PubMed     Text format     Abstract available


  166. LINNINGER A, Hartung GA, Liu BP, Mirkov S, et al
    Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
    Neuro Oncol. 2018 Apr 5. pii: 4962158. doi: 10.1093.
    PubMed     Text format     Abstract available


  167. ELLINGSON BM, Abrey LE, Nelson SJ, Kaufmann TJ, et al
    Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
    Neuro Oncol. 2018 Apr 5. pii: 4962189. doi: 10.1093.
    PubMed     Text format     Abstract available


  168. ELLINGSON BM, Aftab DT, Schwab GM, Hessel C, et al
    Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Neuro Oncol. 2018 Apr 5. pii: 4962211. doi: 10.1093.
    PubMed     Text format     Abstract available


  169. ALEXANDER BM, Cloughesy TF
    Platform trials arrive on time for glioblastoma.
    Neuro Oncol. 2018 Apr 2. pii: 4958219. doi: 10.1093.
    PubMed     Text format    


    March 2018
  170. AKBARI H, Bakas S, Pisapia JM, Nasrallah MP, et al
    In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
    Neuro Oncol. 2018 Mar 30. pii: 4956862. doi: 10.1093.
    PubMed     Text format     Abstract available


  171. BABAK S, Mason WP
    mTOR inhibition in glioblastoma: requiem for a dream?
    Neuro Oncol. 2018 Mar 28. pii: 4955983. doi: 10.1093.
    PubMed     Text format    


  172. NASSIRI F, Aldape K, Zadeh G
    The multiforme of glioblastoma.
    Neuro Oncol. 2018;20:437-438.
    PubMed     Text format    


  173. LEVIN VA
    Drug discovery in neuro-oncology: challenges in the path forward.
    Neuro Oncol. 2018;20:435-436.
    PubMed     Text format    


  174. JORDAN JT, Sanders AE, Armstrong T, Asher T, et al
    Quality improvement in neurology: Neuro-Oncology Quality Measurement Set.
    Neuro Oncol. 2018;20:531-537.
    PubMed     Text format    


  175. HSIEH TH, Liu YR, Chang TY, Liang ML, et al
    Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors.
    Neuro Oncol. 2018;20:519-530.
    PubMed     Text format     Abstract available


  176. BOXERMAN JL, Zhang Z, Safriel Y, Rogg JM, et al
    Prognostic Value of Contrast Enhancement and FLAIR for Survival in Newly Diagnosed Glioblastoma Treated With and Without Bevacizumab: Results from ACRIN 6686.
    Neuro Oncol. 2018 Mar 26. pii: 4953723. doi: 10.1093.
    PubMed     Text format     Abstract available


  177. BROEN MPG, Smits M, Wijnenga MMJ, Dubbink HJ, et al
    The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.
    Neuro Oncol. 2018 Mar 26. pii: 4953716. doi: 10.1093.
    PubMed     Text format     Abstract available


  178. ANGUS SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, et al
    EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Neuro Oncol. 2018 Mar 21. pii: 4947870. doi: 10.1093.
    PubMed     Text format     Abstract available


  179. SAADEH FS, Melamed EF, Rea ND, Krieger MD, et al
    Seizure outcomes of supratentorial brain tumor resection in pediatric patients.
    Neuro Oncol. 2018 Mar 20. pii: 4944459. doi: 10.1093.
    PubMed     Text format     Abstract available


  180. PEDROSA R, Mustafa DA, Soffietti R, Kros JM, et al
    Breast cancer brain metastasis: molecular mechanisms and directions for treatment.
    Neuro Oncol. 2018 Mar 16. pii: 4939604. doi: 10.1093.
    PubMed     Text format     Abstract available


  181. HE J, Zhao Y, Zhao E, Wang X, et al
    Cancer-testis Specific Gene OIP5: A Downstream Gene of E2F1 that Promotes Tumorigenesis and Metastasis in Glioblastoma by Stabilizing E2F1 Signalling.
    Neuro Oncol. 2018 Mar 14. pii: 4934327. doi: 10.1093.
    PubMed     Text format     Abstract available


  182. APPAY R, Tabouret E, Macagno N, Touat M, et al
    IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.
    Neuro Oncol. 2018 Mar 7. pii: 4924365. doi: 10.1093.
    PubMed     Text format    


  183. VANDERBEEK AM, Rahman R, Fell G, Ventz S, et al
    The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
    Neuro Oncol. 2018 Mar 6. pii: 4922286. doi: 10.1093.
    PubMed     Text format     Abstract available


  184. COY S, Rashid R, Lin JR, Du Z, et al
    Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma.
    Neuro Oncol. 2018 Mar 2. pii: 4917565. doi: 10.1093.
    PubMed     Text format     Abstract available


  185. BAGLEY SJ, Desai AS, Linette GP, June CH, et al
    CAR T Cell Therapy for Glioblastoma: Recent Clinical Advances and Future Challenges.
    Neuro Oncol. 2018 Mar 2. pii: 4917531. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  186. PARK JW, Wollmann G, Urbiola C, Fogli B, et al
    Sprouty2 enhances the tumorigenic potential of glioblastoma cells.
    Neuro Oncol. 2018 Feb 23. pii: 4904223. doi: 10.1093.
    PubMed     Text format     Abstract available


  187. OSTROM QT, Rubin JB, Lathia JD, Berens ME, et al
    Females have the survival advantage in glioblastoma.
    Neuro Oncol. 2018 Feb 21. pii: 4883496. doi: 10.1093.
    PubMed     Text format    


  188. PACE A, Walbert T
    Simultaneous care in neuro-oncology.
    Neuro Oncol. 2018;20:302-303.
    PubMed     Text format    


  189. KRUCHKO C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS, et al
    The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone.
    Neuro Oncol. 2018;20:295-298.
    PubMed     Text format    


  190. BLUMENTHAL DT, Won M, Mehta MP, Gilbert MR, et al
    Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group (RTOG) database.
    Neuro Oncol. 2018 Feb 15. pii: 4861801. doi: 10.1093.
    PubMed     Text format     Abstract available


  191. BASKARAN S, Mayrhofer M, Kultima HG, Bergstrom T, et al
    Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages.
    Neuro Oncol. 2018 Feb 15. pii: 4860173. doi: 10.1093.
    PubMed     Text format     Abstract available


  192. CHOI S, Yu Y, Grimmer MR, Wahl M, et al
    Temozolomide-associated Hypermutation in Gliomas.
    Neuro Oncol. 2018 Feb 14. pii: 4857168. doi: 10.1093.
    PubMed     Text format     Abstract available


  193. ZHOU M, Zhou Y, Liao H, Rowland BC, et al
    Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas.
    Neuro Oncol. 2018 Feb 9. pii: 4846845. doi: 10.1093.
    PubMed     Text format     Abstract available


  194. ABOUNADER R
    A new practical and versatile mouse model of proneural glioblastoma.
    Neuro Oncol. 2018 Feb 8. pii: 4842815. doi: 10.1093.
    PubMed     Text format    


  195. ALDAPE K, Amin SB, Ashley DM, Barnholtz-Sloan JS, et al
    Glioma Through the Looking GLASS: Molecular Evolution of Diffuse Gliomas and the Glioma Longitudinal AnalySiS Consortium.
    Neuro Oncol. 2018 Feb 8. pii: 4843984. doi: 10.1093.
    PubMed     Text format     Abstract available


  196. LIAO P, Ostrom QT, Stetson L, Barnholtz-Sloan JS, et al
    Models of Epigenetic Age Capture Patterns of DNA Methylation in Glioma Associated with Molecular Subtype, Survival, and Recurrence.
    Neuro Oncol. 2018 Feb 8. pii: 4844022. doi: 10.1093.
    PubMed     Text format     Abstract available


  197. BRENNER A, Zuniga R, Sun JD, Floyd J, et al
    Hypoxia Activated Evofosfamide for Treatment of Recurrent Bevacizumab-Refractory Glioblastoma: A phase I surgical study.
    Neuro Oncol. 2018 Feb 5. pii: 4838327. doi: 10.1093.
    PubMed     Text format     Abstract available


  198. NHAT TRAN A, Walker K, Harrison DG, Chen W, et al
    Reactive Species Balance via GTP Cyclohydrolase I Regulates Glioblastoma Growth and Tumor Initiating Cell Maintenance.
    Neuro Oncol. 2018 Feb 2. pii: 4835145. doi: 10.1093.
    PubMed     Text format     Abstract available


  199. LOUVRIER C, Pasmant E, Briand-Suleau A, Cohen J, et al
    Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Neuro Oncol. 2018 Feb 2. pii: 4835073. doi: 10.1093.
    PubMed     Text format     Abstract available


  200. MONCAYO G, Grzmil M, Smirnova T, Zmarz P, et al
    SYK Inhibition Blocks Proliferation and Migration of Glioma Cells, and Modifies the Tumor Microenvironment.
    Neuro Oncol. 2018 Feb 1. pii: 4833547. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  201. ALDAVE G, Gonzalez-Huarriz M, Rubio A, Romero JP, et al
    The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.
    Neuro Oncol. 2018 Jan 24. pii: 4823831. doi: 10.1093.
    PubMed     Text format     Abstract available


  202. AUDIA A, Bhat KP
    Ritanserin, a novel agent targeting the mesenchymal subtype of glioblastomas.
    Neuro Oncol. 2018;20:151-152.
    PubMed     Text format    


  203. RUBIN JB, Finlay JL
    Pediatric low-grade gliomas: a brave new world.
    Neuro Oncol. 2018;20:149-150.
    PubMed     Text format    


  204. STROWD RE, Kim AH, Wen PY
    Meeting Update-Society for Neuro-Oncology 2017 Annual Meeting.
    Neuro Oncol. 2018;20:156-159.
    PubMed     Text format    


  205. WARREN KE, Vezina G, Poussaint TY, Warmuth-Metz M, et al
    Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee".
    Neuro Oncol. 2018;20:144-145.
    PubMed     Text format    


  206. HARRELD JH
    Comment on "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee".
    Neuro Oncol. 2018;20:143-144.
    PubMed     Text format    


  207. ALDAPE K
    A change at the helm of Neuro-Oncology.
    Neuro Oncol. 2018;20:1.
    PubMed     Text format    


  208. PRUST ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, et al
    Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss.
    Neuro Oncol. 2018 Jan 5. pii: 4791799. doi: 10.1093.
    PubMed     Text format    


  209. CHIN AL, Moding EJ, Donaldson SS, Gibbs IC, et al
    Survival Impact of Postoperative Radiotherapy Timing in Pediatric and Adolescent Medulloblastoma.
    Neuro Oncol. 2018 Jan 4. pii: 4788577. doi: 10.1093.
    PubMed     Text format     Abstract available


  210. RUDA R, Soffietti R
    Extent of surgery in low-grade gliomas: an old question in a new context.
    Neuro Oncol. 2018 Jan 3. pii: 4788257. doi: 10.1093.
    PubMed     Text format    


    December 2017
  211. PARK J, Shim JK, Kang JH, Choi J, et al
    Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.
    Neuro Oncol. 2017 Dec 23. pii: 4773887. doi: 10.1093.
    PubMed     Text format     Abstract available


  212. MAHLOKOZERA T, Vellimana AK, Li T, Mao DD, et al
    Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastomas.
    Neuro Oncol. 2017 Dec 13. pii: 4737220. doi: 10.1093.
    PubMed     Text format     Abstract available


  213. CALMON R, Puget S, Varlet P, Dangouloff-Ros V, et al
    Cerebral blood flow changes after radiation therapy identifies pseudo-progression in diffuse intrinsic pontine gliomas.
    Neuro Oncol. 2017 Dec 13. pii: 4737113. doi: 10.1093.
    PubMed     Text format     Abstract available


  214. IUS T, Ciani Y, Ruaro ME, Isola M, et al
    A NF-kappaB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.
    Neuro Oncol. 2017 Dec 7. pii: 4708291. doi: 10.1093.
    PubMed     Text format     Abstract available


  215. PEYRE M, Gauchotte G, Giry M, Froehlich S, et al
    De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Neuro Oncol. 2017 Dec 5. pii: 4694050. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  216. GUERRINI-ROUSSEAU L, Dufour C, Varlet P, Masliah-Planchon J, et al
    Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk and prognosis.
    Neuro Oncol. 2017 Nov 24. pii: 4657092. doi: 10.1093.
    PubMed     Text format     Abstract available


  217. PFAFF E, Kessler T, Balasubramanian GP, Berberich A, et al
    Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation - the NCT Neuro Master Match (N2M2) pilot study.
    Neuro Oncol. 2017 Nov 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  218. DOVER LL, Dulaney CR, Williams CP, Fiveash JB, et al
    Hospice care, cancer-directed therapy, and Medicare expenditures among older patients dying with malignant brain tumors.
    Neuro Oncol. 2017 Nov 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  219. ABDELBAKI MS, Boue DR, Finlay JL, Kieran MW, et al
    Desmoplastic Nodular Medulloblastoma in Young Children: A Management Dilemma.
    Neuro Oncol. 2017 Nov 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  220. NASSIRI F, Zadeh G, Aldape K
    IDH mutation testing in gliomas-where do we draw the line?
    Neuro Oncol. 2017 Nov 11. doi: 10.1093.
    PubMed     Text format    


  221. LAKS DR, Oses-Prieto JA, Alvarado AG, Nakashima J, et al
    A Molecular Cascade Modulates MAP1B and Confers Resistance to mTOR Inhibition in Human Glioblastoma.
    Neuro Oncol. 2017 Nov 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  222. SCHAFER N, Proescholdt M, Steinbach JP, Weyerbrock A, et al
    Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
    Neuro Oncol. 2017 Nov 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  223. GONDI V, Mehta MP
    Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis.
    Neuro Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format    


  224. CHINNAIYAN P, Won M, Wen PY, Rojiani AM, et al
    A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.
    Neuro Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  225. CARAGHER SP, Hall RR 3rd, Ahsan R, Ahmed AU, et al
    Monoamines in Glioblastoma: complex biology with therapeutic potential.
    Neuro Oncol. 2017 Nov 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  226. WANG J, Yang ZY, Guo YF, Kuang JY, et al
    Targeting different domains of gap junction protein to control malignant glioma.
    Neuro Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  227. BANASAVADI-SIDDEGOWDA YK, Welker AM, An M, Yang X, et al
    PRMT5 as a druggable target for glioblastoma therapy.
    Neuro Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  228. TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
    Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Neuro Oncol. 2017 Nov 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  229. DEUMELANDT K, Platten M, Ochs K
    Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy.
    Neuro Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format    


  230. OMURO A, Vlahovic G, Lim M, Sahebjam S, et al
    Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.
    Neuro Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  231. GAN HK, Reardon DA, Lassman AB, Merrell R, et al
    Safety, Pharmacokinetics and Antitumor Response of Depatuxizumab Mafodotin as Monotherapy or in Combination with Temozolomide in Patients with Glioblastoma.
    Neuro Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  232. HAYES J, Yu Y, Jalbert LE, Mazor T, et al
    Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  233. PLATTEN M
    EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?
    Neuro Oncol. 2017;19:1425-1426.
    PubMed     Text format    


  234. UNTERRAINER M, Niyazi M, Ruf V, Bartenstein P, et al
    The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
    Neuro Oncol. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format    


  235. FORST D, Adams E, Nipp R, Martin A, et al
    Hospice Utilization in Patients with Malignant Gliomas.
    Neuro Oncol. 2017 Oct 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  236. ELLINGSON BM, Wen PY, Cloughesy TF
    Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.
    Neuro Oncol. 2017 Oct 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  237. ESKILSSON E, Rosland GV, Solecki G, Wang Q, et al
    EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
    Neuro Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  238. RUIZ VY, Praska CE, Armstrong G, Kollmeyer TM, et al
    Molecular Subtyping of Tumors from Patients with Familial Glioma.
    Neuro Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  239. CLOUGHESY TF, Drappatz J, de Groot J, Prados MD, et al
    Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
    Neuro Oncol. 2017 Oct 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  240. JOHN-PAUL K, Bartels U
    Intracystic interferon-alpha in pediatric craniopharyngioma patients-reply.
    Neuro Oncol. 2017;19:1420-1421.
    PubMed     Text format    


  241. PENAS-PRADO M, de Groot J
    CATNON interim results: another triumph of upfront chemotherapy in glioma.
    Neuro Oncol. 2017;19:1287-1288.
    PubMed     Text format    


  242. CAVALHEIRO S
    Intracystic interferon-alpha in pediatric craniopharyngioma patients.
    Neuro Oncol. 2017;19:1419.
    PubMed     Text format    


  243. LOU E
    Can you hear them now? Tumor microtubes form cellular communication networks that protect gliomas from surgical lesions and chemotherapy treatments.
    Neuro Oncol. 2017;19:1289-1291.
    PubMed     Text format    


    September 2017
  244. KICKINGEREDER P, Neuberger U, Bonekamp D, Piechotta PL, et al
    Radiomic subtyping improves disease stratification beyond key molecular, clinical and standard imaging characteristics in patients with glioblastoma.
    Neuro Oncol. 2017 Sep 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  245. MALTA TM, de Souza CF, Sabedot TS, Silva TC, et al
    Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications.
    Neuro Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  246. KAUR S, Ramdzan ZM, Guiot MC, Li L, et al
    CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide.
    Neuro Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  247. SAHM F, Wick A
    ID(H)entifying checkpoint inhibitor candidates among diffuse glioma.
    Neuro Oncol. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format    


  248. BIELAMOWICZ K, Fousek K, Byrd TT, Samaha H, et al
    Trivalent CAR T-cells Overcome Interpatient Antigenic Variability in Glioblastoma.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  249. HEFFRON TP
    Challenges of developing small molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  250. PRIDHAM KJ, Le L, Guo S, Varghese RT, et al
    PIK3CB/p110beta is a Selective Survival Factor for Glioblastoma.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  251. POETSCH N, Woehrer A, Gesperger J, Furtner J, et al
    Visual and semiquantitative 11C-methionine PET: An independent prognostic factor for survival of newly diagnosed and treatment naive gliomas.
    Neuro Oncol. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  252. HARDY KK, Willard VW, Gioia A, Sharkey C, et al
    Attention-mediated neurocognitive profiles in survivors of pediatric brain tumors: Comparison to children with neurodevelopmental ADHD.
    Neuro Oncol. 2017 Sep 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  253. SARKARIA JN, Hu LS, Parney IF, Pafundi DH, et al
    Is the blood-brain barrier really disrupted in all glioblastomas? - A critical assessment of existing clinical data.
    Neuro Oncol. 2017 Sep 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  254. WIJNENGA MMJ, French PJ, Dubbink HJ, Dinjens WNM, et al
    The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological and molecular analysis.
    Neuro Oncol. 2017 Sep 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  255. SHIBAO S, Minami N, Koike N, Fukui N, et al
    Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model.
    Neuro Oncol. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  256. BALASUBRAMANIYAN V, Bhat KP
    Targeting MIR155HG in glioma: a novel approach.
    Neuro Oncol. 2017;19:1152-1153.
    PubMed     Text format    


  257. COONEY T, Lane A, Bartels U, Bouffet E, et al
    Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study.
    Neuro Oncol. 2017;19:1279-1280.
    PubMed     Text format    


  258. SCHNEIDER M, Reitter EM, Kastner MT, Thannesberger J, et al
    Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment.
    Neuro Oncol. 2017;19:1280-1282.
    PubMed     Text format    


  259. GOERIG NL, Frey B, Uberla K, Gaipl U, et al
    A clinician's plea to test glioma patients for CMV.
    Neuro Oncol. 2017;19:1282-1283.
    PubMed     Text format    


  260. NOWOSIELSKI M, Ellingson BM, Chinot OL, Garcia J, et al
    Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio.
    Neuro Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2017
  261. ANDERSEN ZJ, Pedersen M, Weinmayr G, Stafoggia M, et al
    Long-term Exposure to Ambient Air Pollution and Incidence of Brain Tumor: the European Study of Cohorts for Air Pollution Effects (ESCAPE).
    Neuro Oncol. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  262. SZULZEWSKY F, Schwendinger N, Guneykaya D, Cimino PJ, et al
    Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment.
    Neuro Oncol. 2017 Aug 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  263. TAUNK NK, Oh JH, Shukla-Dave A, Beal K, et al
    Early Post-treatment Assessment of MRI Perfusion Biomarkers Can Predict Long-term Response of Lung Cancer Brain Metastases to Stereotactic Radiosurgery.
    Neuro Oncol. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  264. KESSLER T, Sahm F, Sadik A, Stichel D, et al
    Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Neuro Oncol. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  265. KHAGI S, Miller CR
    Putting "multiforme" back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology.
    Neuro Oncol. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format    


  266. GALANIS E, Anderson SK, Miller CR, Sarkaria JN, et al
    Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02.
    Neuro Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  267. DAGMAR D, Proescholdt M, Reinert C, Pietsch T, et al
    Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
    Neuro Oncol. 2017 Aug 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  268. WEN PY, Drappatz J, de Groot J, Prados MD, et al
    Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
    Neuro Oncol. 2017 Aug 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  269. LANG FM, Hossain A, Gumin J, Momin EN, et al
    Mesenchymal Stem Cells as Natural Bio-Factories for Exosomes Carrying miR-124a in the Treatment of Gliomas.
    Neuro Oncol. 2017 Aug 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  270. KARREMANN M, Gielen GH, Hoffmann M, Wiese M, et al
    Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Neuro Oncol. 2017 Aug 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  271. JONES DTW, Kieran MW, Bouffet E, Alexandrescu S, et al
    Pediatric Low-Grade Gliomas: Next Biologically Driven Steps.
    Neuro Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  272. GROSSMAN SA, Kleinberg L
    A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.
    Neuro Oncol. 2017;19:1019-1020.
    PubMed     Text format    


    July 2017
  273. MANDEL JJ, Yust-Katz S, Patel AJ, Cachia D, et al
    Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.
    Neuro Oncol. 2017 Jul 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  274. GARNIER D, Meehan B, Kislinger T, Daniel P, et al
    Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
    Neuro Oncol. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  275. PHILIP J, Collins A, Brand C, Sundararajan V, et al
    A Proposed Framework of Supportive and Palliative Care for people with High Grade Glioma.
    Neuro Oncol. 2017 Jul 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  276. BHERE D, Tamura K, Wakimoto H, Choi SH, et al
    microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
    Neuro Oncol. 2017 Jul 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  277. SPERANZA MC, Passaro C, Ricklefs F, Kasai K, et al
    Preclinical investigation of gene-mediated cytotoxic immunotherapy and checkpoint blockade in glioblastoma.
    Neuro Oncol. 2017 Jul 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  278. LEVESLEY J, Steele L, Bruning-Richardson A, Davison A, et al
    Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
    Neuro Oncol. 2017 Jul 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  279. SCHREIBER JE, Palmer SL, Conklin HM, Mabbott DJ, et al
    Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study.
    Neuro Oncol. 2017 Jul 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  280. AOKI K, Nakamura H, Suzuki H, Matsuo K, et al
    Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Jul 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  281. WICK A, Kessler T, Elia AEH, Winkler F, et al
    Glioblastoma in the elderly: solid conclusions built on shifting sand?
    Neuro Oncol. 2017 Jul 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  282. SHAN X, Fan X, Liu X, Zhao Z, et al
    Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis.
    Neuro Oncol. 2017 Jul 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  283. COULDWELL WT, Cannon-Albright LA
    A description of familial clustering of meningiomas in the Utah population.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  284. WU S, Wang S, Gao F, Li L, et al
    Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  285. JAHAN N, Talat H, Curry WT
    Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  286. RAHME GJ, Luikart BW, Cheng C, Israel MA, et al
    A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  287. TIROSH I, Suva ML
    Dissecting human gliomas by single-cell RNA sequencing.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  288. OKADA H, Thorne SH
    Is the immune response a friend or foe for viral therapy of glioma?
    Neuro Oncol. 2017;19:882-883.
    PubMed     Text format    


  289. ZHANG Z, Chan AK, Ding X, Li Y, et al
    Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
    Neuro Oncol. 2017;19:1008-1010.
    PubMed     Text format    


    June 2017
  290. OLMEZ I, Love S, Xiao A, Manigat L, et al
    Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.
    Neuro Oncol. 2017 Jun 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  291. QIAN Y, Maruyama S, Kim H, Pollom EL, et al
    Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.
    Neuro Oncol. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  292. DEWITT JC, Jordan JT, Frosch MP, Samore WR, et al
    Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.
    Neuro Oncol. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  293. JIN L, Ge H, Long Y, Yang C, et al
    CD70, a novel target of CAR-T-cell therapy for gliomas.
    Neuro Oncol. 2017 Jun 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  294. DIAMOND EL, Prigerson HG, Correa DC, Reiner A, et al
    Prognostic Awareness, Prognostic Communication, and Cognitive Function in Patients with Malignant Glioma.
    Neuro Oncol. 2017 Jun 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  295. GUTMANN DH
    Caddyshack therapeutics: overcoming glioblastoma adaptation.
    Neuro Oncol. 2017 Jun 16. doi: 10.1093.
    PubMed     Text format    


  296. GALLDIKS N, Albert NL, Sommerauer M, Grosu AL, et al
    PET Imaging in Patients with Meningioma - Report of the RANO/PET Group.
    Neuro Oncol. 2017 Jun 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  297. WU J, Frady LN, Bash RE, Cohen SM, et al
    MerTK as a therapeutic target in glioblastoma.
    Neuro Oncol. 2017 Jun 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  298. KIERAN MW, Chisholm J, Casanova M, Brandes AA, et al
    Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
    Neuro Oncol. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  299. MORROW AM, Morgan RM, Villano JL
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials-impact of psychogenic non-epileptic seizures.
    Neuro Oncol. 2017 Jun 6. doi: 10.1093.
    PubMed     Text format    


  300. WANG X, Holgado BL, Ramaswamy V, Mack S, et al
    "miR miR on the wall, who's the most malignant medulloblastoma miR of them all?"
    Neuro Oncol. 2017 Jun 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  301. ZHOU X, Xie S, Wu S, Qi Y, et al
    Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor.
    Neuro Oncol. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  302. SEPULVEDA-SANCHEZ JM, Vaz MA, Balana C, Gil-Gil M, et al
    Phase II trial of dacomitinib, a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Neuro Oncol. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  303. ABUDUMIJITI A, Chan AK, Shi Z, Li Y, et al
    Adult IDH Wild-type Lower-grade Gliomas Should Be Further Stratified.
    Neuro Oncol. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  304. ZHU C, Kros JM, Cheng C, Mustafa D, et al
    The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.
    Neuro Oncol. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  305. NABORS LB
    When less is better: care of the elderly with glioblastoma.
    Neuro Oncol. 2017 May 26. doi: 10.1093.
    PubMed     Text format    


  306. GLASS JO, Ogg RJ, Hyun JW, Harreld JH, et al
    Disrupted development and integrity of frontal white matter in patients treated for pediatric medulloblastoma.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  307. KESARWANI P, Kant S, Prabhu A, Chinnaiyan P, et al
    The interplay between metabolic remodeling and immune regulation in glioblastoma.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  308. PRABHU A, Kesarwani P, Kant S, Graham SF, et al
    Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  309. KIERAN MW
    Lessons learned from diffuse intrinsic pontine glioma: how a terrible disease forced us to think better.
    Neuro Oncol. 2017 May 24. doi: 10.1093.
    PubMed     Text format    


  310. JACKSON S, ElAli A, Virgintino D, Gilbert MR, et al
    Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease.
    Neuro Oncol. 2017 May 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  311. KARIMI S, Vyas MV, Gonen L, Tabasinejad R, et al
    Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  312. BERGHOFF AS, Kiesel B, Widhalm G, Wilhelm D, et al
    Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  313. NOWOSIELSKI M, Galldiks N, Iglseder S, Kickingereder P, et al
    Diagnostic Challenges in Meningioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  314. COLMAN H
    Toward more informative biomarker-based clinical trials in glioblastoma.
    Neuro Oncol. 2017 May 17. doi: 10.1093.
    PubMed     Text format    


  315. GROSSMANN P, Narayan V, Chang K, Rahman R, et al
    Quantitative Imaging Biomarkers for Risk Stratification of Patients with Recurrent Glioblastoma Treated with Bevacizumab.
    Neuro Oncol. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  316. KILDAY JP, Caldarelli M, Massimi L, Chen RH, et al
    Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN.
    Neuro Oncol. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  317. SHANKAR GM, Santagata S
    BAP1 mutations in high-grade meningioma: implications for patient care.
    Neuro Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  318. SCHMIDT C, Schubert NA, Brabetz S, Mack N, et al
    Pre-clinical drug screen reveals topotecan, actinomycin D and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
    Neuro Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  319. YESILOZ U, Kirches E, Hartmann C, Scholz J, et al
    Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Neuro Oncol. 2017 May 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  320. SILGINER M, Nagy S, Happold C, Schneider H, et al
    Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma.
    Neuro Oncol. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  321. NARLOCH JL, Farber SH, Sammons S, McSherry F, et al
    Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.
    Neuro Oncol. 2017 May 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  322. MASON W
    NANO, a practical scale for neurologic assessments in patients with brain tumors?
    Neuro Oncol. 2017;19:603-604.
    PubMed     Text format    


  323. GITTLEMAN H, Lim D, Kattan MW, Chakravarti A, et al
    An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    Neuro Oncol. 2017;19:669-677.
    PubMed     Text format     Abstract available


  324. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2017;19:719-725.
    PubMed     Text format     Abstract available


  325. TERRIER LM, Bauchet L, Rigau V, Amelot A, et al
    Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database.
    Neuro Oncol. 2017;19:678-688.
    PubMed     Text format     Abstract available


  326. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2017;19:660-668.
    PubMed     Text format     Abstract available


  327. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2017;19:636-647.
    PubMed     Text format     Abstract available


  328. NAYAK L, DeAngelis LM, Brandes AA, Peereboom DM, et al
    The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
    Neuro Oncol. 2017;19:625-635.
    PubMed     Text format     Abstract available


  329. ZHU C, Mustafa D, Zheng PP, van der Weiden M, et al
    Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.
    Neuro Oncol. 2017;19:648-659.
    PubMed     Text format     Abstract available


  330. KLINE CN, Joseph NM, Grenert JP, van Ziffle J, et al
    Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
    Neuro Oncol. 2017;19:699-709.
    PubMed     Text format     Abstract available


    April 2017
  331. FIGUEROA JM, Skog J, Akers J, Li H, et al
    Detection of wtEGFR Amplification and EGFRvIII Mutation in CSF-Derived Extracellular Vesicles of Glioblastoma Patients.
    Neuro Oncol. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  332. WARREN KE, Vezina G, Poussaint TY, Warmuth-Metz M, et al
    Response Assessment in Medulloblastoma and Leptomeningeal Seeding Tumors: Recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee.
    Neuro Oncol. 2017 Apr 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  333. CAGNEY DN, Martin AM, Catalano PJ, Redig AJ, et al
    Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study.
    Neuro Oncol. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  334. BROKINKEL B, Hess K, Mawrin C
    Brain invasion in Meningiomas - Clinical considerations and impact of neuropathological evaluation: A systematic Review.
    Neuro Oncol. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  335. WEIL S, Osswald M, Solecki G, Grosch J, et al
    Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
    Neuro Oncol. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  336. VITUCCI M, Irvin DM, McNeill RS, Schmid RS, et al
    Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.
    Neuro Oncol. 2017 Apr 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  337. MITCHELL LA, Lopez Espinoza F, Mendoza D, Kato Y, et al
    Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
    Neuro Oncol. 2017 Apr 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  338. THOMPSON EM, Keir ST, Venkatraman T, Lascola C, et al
    The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.
    Neuro Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  339. LIN AL, DeAngelis LM
    Reappraising the 2016 WHO classification for diffuse glioma.
    Neuro Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format    


  340. WEN PY, Jiang T, Schiff D
    How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.
    Neuro Oncol. 2017;19:459-460.
    PubMed     Text format    


  341. GROSSMAN SA, Schreck KC, Ballman K, Alexander B, et al
    Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2017;19:469-474.
    PubMed     Text format    


  342. GROSSHANS DR, Mohan R, Gondi V, Shih HA, et al
    The role of image-guided intensity modulated proton therapy in glioma.
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  343. SAHGAL A, Ruschin M, Ma L, Verbakel W, et al
    Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues.
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  344. GRANBERG KJ, Annala M, Lehtinen B, Kesseli J, et al
    Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
    Neuro Oncol. 2017 Apr 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  345. CAO Y, Tseng CL, Balter JM, Teng F, et al
    MR-guided radiation therapy: transformative technology and its role in the central nervous system.
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  346. KIRKPATRICK JP, Soltys SG, Lo SS, Beal K, et al
    The radiosurgery fractionation quandary: single fraction or hypofractionation?
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  347. CHAMBERLAIN M, Junck L, Brandsma D, Soffietti R, et al
    Leptomeningeal metastases: a RANO proposal for response criteria.
    Neuro Oncol. 2017;19:484-492.
    PubMed     Text format     Abstract available


  348. MYNAREK M, Pizer B, Dufour C, van Vuurden D, et al
    Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data.
    Neuro Oncol. 2017;19:576-585.
    PubMed     Text format     Abstract available


  349. BATCHELOR TT, Gerstner ER, Ye X, Desideri S, et al
    Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-beta tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Neuro Oncol. 2017;19:567-575.
    PubMed     Text format     Abstract available


  350. HARDCASTLE J, Mills L, Malo CS, Jin F, et al
    Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Neuro Oncol. 2017;19:493-502.
    PubMed     Text format     Abstract available


    March 2017
  351. AHMED KA, Berglund AE, Welsh EA, Naghavi AO, et al
    The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity.
    Neuro Oncol. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format    


  352. HUANG R
    Response assessment in high-grade glioma: tumor volume as endpoint.
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format    


  353. FOULADI M, Pfister SM
    MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format    


  354. MCNEILL RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, et al
    Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  355. COHEN KJ, Jabado N, Grill J
    Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  356. BLUMENTHAL DT, Gorlia T, Gilbert MR, Kim MM, et al
    Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  357. WU X, Wang Y, Yu T, Nie E, et al
    Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  358. WANG C, Kaprealian TB, Suh JH, Kubicky CD, et al
    Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  359. HODGES TR, Ott M, Xiu J, Gatalica Z, et al
    Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  360. HOLDHOFF M, Ye X, Supko JG, Nabors LB, et al
    Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Neuro Oncol. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  361. LAWLER SE
    Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment.
    Neuro Oncol. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format    


  362. JEON MS, Dhillon HM, Agar MR
    Sleep disturbance of adults with a brain tumor and their family caregivers: a systematic review.
    Neuro Oncol. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  363. HU X, Martinez-Ledesma E, Zheng S, Kim H, et al
    Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Neuro Oncol. 2017 Mar 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  364. MEI X, Chen YS, Chen FR, Xi SY, et al
    Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.
    Neuro Oncol. 2017 Mar 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  365. ALVAREZ-BRECKENRIDGE C, Brastianos PK
    SMO mutant olfactory groove meningiomas-the next in line for targeted therapy.
    Neuro Oncol. 2017;19:305-306.
    PubMed     Text format    


  366. JENKINSON MD, Santarius T, Zadeh G, Aldape KD, et al
    Atypical meningioma-is it time to standardize surgical sampling techniques?
    Neuro Oncol. 2017;19:453-454.
    PubMed     Text format    


  367. YANG W, Garzon-Muvdi T, Braileanu M, Porras JL, et al
    Primary intramedullary spinal cord lymphoma: a population-based study.
    Neuro Oncol. 2017;19:414-421.
    PubMed     Text format     Abstract available


  368. TABOURET E, Houillier C, Martin-Duverneuil N, Blonski M, et al
    Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.
    Neuro Oncol. 2017;19:422-429.
    PubMed     Text format     Abstract available


  369. ALDAPE K, Nejad R, Louis DN, Zadeh G, et al
    Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community.
    Neuro Oncol. 2017;19:336-344.
    PubMed     Text format     Abstract available


  370. BENTLEY RT, Ahmed AU, Yanke AB, Cohen-Gadol AA, et al
    Dogs are man's best friend: in sickness and in health.
    Neuro Oncol. 2017;19:312-322.
    PubMed     Text format     Abstract available


    February 2017
  371. ARIF T, Kerlin Y, Nakdimon I, Benharroch D, et al
    VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  372. BANERJEE A, Jakacki RI, Onar-Thomas A, Wu S, et al
    A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  373. COTE DJ, Downer MK, Zoltick ES, Smith TR, et al
    ABO blood group and risk of glioma.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    


  374. ANDERSON JL, Muraleedharan R, Oatman N, Klotter A, et al
    The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Neuro Oncol. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  375. HUANG YT, Zhang Y, Wu Z, Michaud DS, et al
    Genotype-based gene signature of glioma risk.
    Neuro Oncol. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  376. VAN DEN BENT MJ, Weller M, Wen PY, Kros JM, et al
    A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.
    Neuro Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  377. TANGUTURI SK, Trippa L, Ramkissoon SH, Pelton K, et al
    Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.
    Neuro Oncol. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  378. FREYSCHLAG CF, Kerschbaumer J, Thome C
    Comment on: Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
    Neuro Oncol. 2017 Feb 18. doi: 10.1093.
    PubMed     Text format    


  379. GAHRMANN R, van den Bent M, van der Holt B, Vernhout RM, et al
    Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  380. HEINZEL A, Muller D, Yekta-Michael SS, Ceccon G, et al
    O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  381. D'ALESSANDRIS QG, Biffoni M, Martini M, Runci D, et al
    The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  382. ABOU-EL-ARDAT K, Seifert M, Becker K, Eisenreich S, et al
    Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  383. MEYRONET D, Esteban-Mader M, Bonnet C, Joly MO, et al
    Characteristics of H3 K27M-mutant gliomas in adults.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  384. TEGLASI V, Reiniger L, Fabian K, Pipek O, et al
    Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  385. RUDA R, Soffietti R
    Controversies in management of low-grade gliomas in light of new data from clinical trials.
    Neuro Oncol. 2017;19:143-144.
    PubMed     Text format    


  386. RODDY E, Mueller S
    Response to "Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of paediatric brain tumors".
    Neuro Oncol. 2017;19:299-300.
    PubMed     Text format    


  387. PASSOS J, Nzwalo H, Marques J, Azevedo A, et al
    Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of pediatric brain tumors.
    Neuro Oncol. 2017;19:298-299.
    PubMed     Text format    


  388. SOFFIETTI R, Abacioglu U, Baumert B, Combs SE, et al
    Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).
    Neuro Oncol. 2017;19:162-174.
    PubMed     Text format     Abstract available


  389. CHANG S, Zhang P, Cairncross JG, Gilbert MR, et al
    Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
    Neuro Oncol. 2017;19:252-258.
    PubMed     Text format     Abstract available


  390. MIRANDA-FILHO A, Pineros M, Soerjomataram I, Deltour I, et al
    Cancers of the brain and CNS: global patterns and trends in incidence.
    Neuro Oncol. 2017;19:270-280.
    PubMed     Text format     Abstract available


    January 2017
  391. ZHOU H, Vallieres M, Bai HX, Su C, et al
    MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Jan 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  392. ANTONIOS JP, Soto H, Everson RG, Moughon D, et al
    Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Neuro Oncol. 2017 Jan 23. pii: now287. doi: 10.1093.
    PubMed     Text format     Abstract available


  393. RAMKISSOON SH, Bandopadhayay P, Hwang J, Ramkissoon LA, et al
    Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
    Neuro Oncol. 2017 Jan 19. pii: now294. doi: 10.1093.
    PubMed     Text format     Abstract available


  394. COLWELL N, Larion M, Giles AJ, Seldomridge AN, et al
    Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.
    Neuro Oncol. 2017 Jan 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  395. BERGHOFF AS, Wolpert F, Holland-Letz T, Koller R, et al
    Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.
    Neuro Oncol. 2017 Jan 17. pii: now290. doi: 10.1093.
    PubMed     Text format     Abstract available


  396. BOETTO J, Bielle F, Sanson M, Peyre M, et al
    SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Neuro Oncol. 2017 Jan 12. pii: now276. doi: 10.1093.
    PubMed     Text format     Abstract available


  397. AYUSO JM, Monge R, Martinez-Gonzalez A, Virumbrales-Munoz M, et al
    Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events.
    Neuro Oncol. 2017 Jan 6. pii: now230. doi: 10.1093.
    PubMed     Text format     Abstract available


  398. TENG J, Carla da Hora C, Kantar RS, Nakano I, et al
    Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
    Neuro Oncol. 2017 Jan 6. pii: now253. doi: 10.1093.
    PubMed     Text format     Abstract available


  399. CHAMBERLAIN MC, Baik CS, Gadi VK, Bhatia S, et al
    Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
    Neuro Oncol. 2017;19:i1-i24.
    PubMed     Text format     Abstract available


  400. BOWMAN RL, Wang Q, Carro A, Verhaak RG, et al
    GlioVis data portal for visualization and analysis of brain tumor expression datasets.
    Neuro Oncol. 2017;19:139-141.
    PubMed     Text format    


  401. GUPTA NK, Nolan A, Omuro A, Reid EG, et al
    Long-term survival in AIDS-related primary central nervous system lymphoma.
    Neuro Oncol. 2017;19:99-108.
    PubMed     Text format     Abstract available


  402. RALEIGH DR, Solomon DA, Lloyd SA, Lazar A, et al
    Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.
    Neuro Oncol. 2017;19:78-88.
    PubMed     Text format     Abstract available


    December 2016
  403. WIEDMANN MK, Brunborg C, Di Ieva A, Lindemann K, et al
    The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.
    Neuro Oncol. 2016 Dec 31. pii: now272. doi: 10.1093.
    PubMed     Text format     Abstract available


  404. CICONE F, Galldiks N, Minniti G, Filss CP, et al
    Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury.
    Neuro Oncol. 2016 Dec 31. pii: now283. doi: 10.1093.
    PubMed     Text format    


  405. YOUNG RJ, Yang TJ, Hatzoglou V, Ulaner G, et al
    "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.
    Neuro Oncol. 2016 Dec 31. pii: now286. doi: 10.1093.
    PubMed     Text format    


  406. MARISETTY AL, Singh SK, Nguyen TN, Coarfa C, et al
    REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.
    Neuro Oncol. 2016 Dec 31. pii: now232. doi: 10.1093.
    PubMed     Text format     Abstract available


  407. ROTH P, Valavanis A, Weller M
    Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
    Neuro Oncol. 2016 Dec 29. pii: now265. doi: 10.1093.
    PubMed     Text format    


  408. KING AA, Seidel K, Di C, Leisenring WM, et al
    Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study.
    Neuro Oncol. 2016 Dec 29. pii: now242. doi: 10.1093.
    PubMed     Text format     Abstract available


  409. REARDON DA, Lassman AB, van den Bent M, Kumthekar P, et al
    Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
    Neuro Oncol. 2016 Dec 29. pii: now257. doi: 10.1093.
    PubMed     Text format     Abstract available


  410. TSCHERPEL C, Dunkl V, Ceccon G, Stoffels G, et al
    The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Neuro Oncol. 2016 Dec 29. pii: now243. doi: 10.1093.
    PubMed     Text format     Abstract available


  411. ZHANG AS, Ostrom QT, Kruchko C, Rogers L, et al
    Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.
    Neuro Oncol. 2016 Dec 29. pii: now252. doi: 10.1093.
    PubMed     Text format     Abstract available


  412. ZAMANIPOOR NAJAFABADI AH, Peeters MC, Dirven L, Lobatto DJ, et al
    Impaired health-related quality of life in meningioma patients-a systematic review.
    Neuro Oncol. 2016 Dec 29. pii: now250. doi: 10.1093.
    PubMed     Text format     Abstract available


  413. TOONEN JA, Ma Y, Gutmann DH
    Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
    Neuro Oncol. 2016 Dec 29. pii: now267. doi: 10.1093.
    PubMed     Text format     Abstract available


  414. LIU TT, Achrol AS, Mitchell LA, Rodriguez SA, et al
    Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment.
    Neuro Oncol. 2016 Dec 22. pii: now270. doi: 10.1093.
    PubMed     Text format     Abstract available


  415. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  416. LEE J, Hoxha E, Song HR
    A novel NFIA-NFkappaB feed-forward loop contributes to glioblastoma cell survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  417. PENG S, Dhurv H, Armstrong B, Salhia B, et al
    Integrated genomic analysis of survival outliers in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  418. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  419. KLEIN M
    Lesion momentum as explanation for preoperative neurocognitive function in patients with malignant glioma.
    Neuro Oncol. 2016;18:1595-1596.
    PubMed     Text format    


  420. SCHIFF D
    Molecular profiling optimizes the treatment of low-grade glioma.
    Neuro Oncol. 2016;18:1593-1594.
    PubMed     Text format    


    November 2016
  421. LASORELLA A, Sanson M, Iavarone A
    FGFR-TACC gene fusions in human glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  422. SHANKAR GM, Abedalthagafi M, Vaubel RA, Merrill PH, et al
    Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
    Neuro Oncol. 2016 Nov 9. doi: 10.1093.
    PubMed     Text format    


  423. ARMSTRONG FD
    Evidence of cerebral microbleeds and neurocognitive impairment following cranial radiation therapy for pediatric brain tumors: a new opportunity for improved care.
    Neuro Oncol. 2016;18:1470-1471.
    PubMed     Text format    


    October 2016
  424. YAGHI NK, Wei J, Hashimoto Y, Kong LY, et al
    Immune modulatory nanoparticle therapeutics for intracerebral glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  425. MENEI P, Clavreul A, Lemee JM
    Response To "Glioma Resection and Tumor Recurrence: Back To Semmelweis".
    Neuro Oncol. 2016.
    PubMed     Text format    


  426. RATEL D, van der Sanden B, Wion D
    Glioma resection and tumor recurrence: back to Semmelweis.
    Neuro Oncol. 2016.
    PubMed     Text format    


    September 2016
  427. PACKER RJ, Pfister S, Bouffet E, Avery R, et al
    Pediatric low-grade gliomas: implications of the biologic era.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  428. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  429. AVILA EK, Chamberlain M, Schiff D, Reijneveld JC, et al
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  430. WAGNER S, Lanfermann H, Eichner G, Gufler H, et al
    Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  431. PINHEIRO KV, Alves C, Buendia M, Gil MS, et al
    Targeting tyrosine receptor kinase B in gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  432. GUNDEMIR S, Monteagudo A, Akbar A, Keillor JW, et al
    The complex role of transglutaminase 2 in glioblastoma proliferation.
    Neuro Oncol. 2016 Sep 2. doi: 10.1093.
    PubMed     Text format    


    February 2016
  433. BAUMGARTEN P, Blank AE, Franz K, Hattingen E, et al
    Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Neuro Oncol. 2016;18:173-83.
    PubMed     Text format     Abstract available


  434. RUDA R, Bosa C, Magistrello M, Franchino F, et al
    Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
    Neuro Oncol. 2016;18:261-8.
    PubMed     Text format     Abstract available


    January 2016
  435. ROUSE C, Gittleman H, Ostrom QT, Kruchko C, et al
    Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010.
    Neuro Oncol. 2016;18:70-7.
    PubMed     Text format     Abstract available


  436. LEE JK, Chang N, Yoon Y, Yang H, et al
    USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.
    Neuro Oncol. 2016;18:37-47.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: